Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.7 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 45.1× Tango Therapeutics Inc.'s market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| TNGX | VWO | |
|---|---|---|
Market Cap | $3.74B | $168.50B |
Volume | 3,438,781 | 5,654,578 |
Sector | Health | — |
52-Week High | $32.90 | $61.44 |
52-Week Low | $7.50 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VWO trades at $59.68, down 0.08% on the day, with a neutral technical signal. The ETF's performance is influenced by mixed regional exposures, with strength in Taiwan's AI and semiconductor sectors but headwinds from China's economic slowdown. Recent news highlights institutional accumulation and comparisons with other international ETFs, emphasizing its emerging markets focus and 0.06% expense ratio.
The outlook for VWO hinges on emerging market dynamics, particularly tech growth in Taiwan versus China's recovery. Risks include concentrated regional exposure and currency fluctuations. Analyst sentiment is balanced, with technical indicators neutral but institutional interest growing, suggesting cautious optimism for long-term diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
